Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2024
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III TrialKarim Fizazi, Gwénaël Le Teuff, Aude Fléchon, et al.
BMC Cancer|December 3, 2021
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)Nieves Martinez Chanza, Louisa Soukane, Philippe Barthelemy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid TumorsLuis Teixeira, Jacques Medioni, Julie Garibal, et al.
The Lancet. Oncology|December 3, 2014
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trialKarim Fizazi, Lance Pagliaro, Agnes Laplanche, et al.
European Urology|November 18, 2021
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC TrialGiulia Baciarello, Remy Delva, Gwenaelle Gravis, et al.
European Urology Oncology|January 4, 2026
Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate CancerFrançois Rozet, Alain Ruffion, Pablo Lemercier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial CancerDavid J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trialKarim Fizazi, Francois Lesaunier, Remy Delva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark TrialsJoaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
European Urology|November 23, 2019
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines CommitteesJ Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Pageof 4